Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)

NCT03634241 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT03634241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03634241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Arm, Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Completed
Start date
November 13, 2018
Completion date
March 11, 2026
Enrollment
45 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung non-small cell carcinoma, stage i lung cancer ajcc v8, stage ia1 lung cancer ajcc v8, stage ia2 lung cancer ajcc v8, stage ia3 lung cancer ajcc v8, stage ib lung cancer ajcc v8, stage ii lung cancer ajcc v8, stage iia lung cancer ajcc v8, stage iib lung cancer ajcc v8